Replies to post #124708 on Biotech Values

[linhdtu]

So MNYC, did T/A help you spot DNDN ?

It would have been a fat profit. Last I check there are more shorts on mnta (16%) than dndn (11%) as of jul 15 according to yahoo.

So what that means most shorts missed out on dndn.

OTOH, if you are counting on the inherent high volatility of biotechs being amplified by a choppy general mkt to make a quick profit shorting on any big mkt move down then I could say that I often take the other side of what you call shorting.

I would buy a biotech with high volatility on a sharp move by the general mkt and sell later when it snapped back. I have done that many times in the past with reasonable success. Whether you win or I win depends on the general mkt , which neither you nor I can predict. If the wind is at my back ( ie the crash is short lived ) I make a profit, if it blows your way you profit.

What I mean by it takes higher skill shorting than being long is of the fundamental short. Take for example, the many blow ups recently of chinese reverse mergers listed here in the US. To be successful, one actually has to have people on the ground checking the facts. Something which is definitely way overhead for the retailer shorts.

I have come to respect hedge funds. They do the dirty digging and if they profit by finding contradictory evidence , I consider they have earned their profit.

[DewDiligence]

I search for stocks specifically on chart T/A and developments in the sector or stock-specific DD. If you can nail those it's pretty easy $$$.

Hogwash. Biotech investing is not easy and it never has been.